Preprint: B.1.617 coronavirus variants show enhanced spike cleavage by furin

“The spike (S) glycoprotein of the SARS-CoV-2 virus that emerged in 2019 contained a suboptimal furin cleavage site at the S1/S2 junction with the sequence 681 PRRAR/S 686. ...More...

France: 46 cases of B.1.1.7 with E484Q mutation in Bordeaux coronavirus outbreak of VOC 20I/484Q

The French city of Bordeaux is to fast-track vaccinations for residents in one neighbourhood, opening access the jab for all adults after nearly 50 people tested positive for a “very rare” variant of Covid-19. 

...More...

India: Covaxin and Covishield vaccines invoke 50% fewer antibodies against B.1.617 coronavirus variant

Scientists at the Indian National Institute of Virology (NIV), Pune, have found that both Covaxin and Covishield produce half as many antibodies against the B.1.617 variant of the novel coronavirus as against the ‘original’ B.1 variant....More...

WHO: Newly designated VOC within lineage B.1.617 – update on Delta coronavirus variant

In consultation with the WHO SARS-CoV-2 Virus Evolution Working Group, WHO has determined that viruses within the lineage B.1.617 have been characterized as a VOC....More...

WHO: B.1.617 Delta coronavirus strain is now a Variant of Concern or VOC

A World Health Organization official said Monday it is reclassifying the Indian Sars-Cov-2 variant B.1.617 as a “variant of concern,” indicating that it’s become a global health threat.

...More...

India: B1617 twice as infectious as UK coronavirus variant B117

Early indications from an analysis of the growth of the B.1.617 variant of the Covid-19 virus has shown it to be at least twice as infectious as the UK variant and thrice as infectious as the variant behind last year’s Covid-19 wave....More...

UK government poised to declare Delta coronavirus B.1.617 a Variant of Concern or VOC

The UK government is thought to have detected more than 40 clusters of the Indian Covid variant B.1.617 in the UK, and is on the verge of declaring it a “variant of concern”.

...More...